MA49460A - Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 - Google Patents

Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1

Info

Publication number
MA49460A
MA49460A MA049460A MA49460A MA49460A MA 49460 A MA49460 A MA 49460A MA 049460 A MA049460 A MA 049460A MA 49460 A MA49460 A MA 49460A MA 49460 A MA49460 A MA 49460A
Authority
MA
Morocco
Prior art keywords
gipr
glp
agonists
association
reduction
Prior art date
Application number
MA049460A
Other languages
English (en)
Inventor
Darren L Bates
Pavel Bondarenko
Irwin Chen
Todd Hager
David J Lloyd
Mark L Michaels
Xiaoshan Min
Donghui Shi
Aiko Umeda
Zhulun Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49460(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA49460A publication Critical patent/MA49460A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049460A 2017-06-20 2018-06-20 Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 MA49460A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762522559P 2017-06-20 2017-06-20

Publications (1)

Publication Number Publication Date
MA49460A true MA49460A (fr) 2020-04-29

Family

ID=62904598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049460A MA49460A (fr) 2017-06-20 2018-06-20 Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1

Country Status (20)

Country Link
US (1) US20210087286A1 (fr)
EP (1) EP3642239A1 (fr)
JP (2) JP7237853B2 (fr)
KR (1) KR20200019122A (fr)
CN (1) CN110831969B (fr)
AU (1) AU2018288854A1 (fr)
BR (1) BR112019024410A2 (fr)
CA (1) CA3062194A1 (fr)
CL (1) CL2019003332A1 (fr)
CO (1) CO2019013008A2 (fr)
CR (1) CR20190532A (fr)
EA (1) EA201992502A1 (fr)
JO (1) JOP20190268A1 (fr)
MA (1) MA49460A (fr)
MX (1) MX2019013919A (fr)
PE (1) PE20200013A1 (fr)
PH (1) PH12019502603A1 (fr)
SA (1) SA519410598B1 (fr)
WO (1) WO2018237097A1 (fr)
ZA (1) ZA201907259B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112824A2 (fr) 2015-12-23 2017-06-29 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2021202013A1 (fr) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anticorps anti-gipr et ses procédés d'utilisation
EP4352104A1 (fr) * 2021-06-09 2024-04-17 Swiftnovo Therapeutics Inc. Agents thérapeutiques et méthodes de traitement ou de réduction de troubles métaboliques
CN117659189A (zh) * 2022-09-08 2024-03-08 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
EP0652950B1 (fr) 1992-07-24 2007-12-19 Amgen Fremont Inc. Production d'anticorps xenogeniques
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
EP0759170B1 (fr) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Methodes d'utilisation de protéine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
WO1998024464A1 (fr) * 1996-12-03 1998-06-11 Trustees Of Boston University Antagonistes specifiques du polypeptide glucodependant insulinotrope (gip)
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
ES2247676T3 (es) 1997-01-07 2006-03-01 Amylin Pharmaceuticals, Inc. Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
ES2291017T3 (es) 1998-02-13 2008-02-16 Amylin Pharmaceuticals, Inc. Efectos inotropicos y diureticos de la exendina y glp-1.
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2000020592A1 (fr) * 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Peptide glucodependant insulinotrope utilise comme hormone osteotrope
WO2000037098A1 (fr) 1998-12-22 2000-06-29 Eli Lilly And Company Formulation de longue conservation de peptide-1 de type glucagon
US6872700B1 (en) 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
WO2001051078A1 (fr) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
CA2417590C (fr) * 2000-05-16 2009-08-11 Sanwa Kagaku Kenkyusho Co., Ltd Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite
WO2003055914A2 (fr) * 2001-12-21 2003-07-10 7Tm Pharma A/S Recepteurs modifies pour la recherche de ligands therapeutiques
AU2003237933A1 (en) 2002-06-11 2003-12-22 Cellartis Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
EP2422807A3 (fr) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
RU2368622C2 (ru) 2004-04-13 2009-09-27 Ф.Хоффманн-Ля Рош Аг Антитела к р-селектину
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2005319432A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Ｈｓａ-관련 조성물 및 사용방법
RU2607014C2 (ru) 2011-03-29 2017-01-10 Рош Гликарт Аг Fc варианты антитела
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
DK3083683T3 (da) * 2013-12-17 2021-01-25 Mhs Care Innovation Llc Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2017112824A2 (fr) * 2015-12-23 2017-06-29 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1

Also Published As

Publication number Publication date
EP3642239A1 (fr) 2020-04-29
JP7237853B2 (ja) 2023-03-13
JP2020524658A (ja) 2020-08-20
JOP20190268A1 (ar) 2019-11-20
MX2019013919A (es) 2020-01-21
CR20190532A (es) 2020-01-10
PE20200013A1 (es) 2020-01-06
SA519410598B1 (ar) 2023-02-19
CO2019013008A2 (es) 2020-01-17
PH12019502603A1 (en) 2020-07-13
US20210087286A1 (en) 2021-03-25
EA201992502A1 (ru) 2020-04-22
KR20200019122A (ko) 2020-02-21
WO2018237097A1 (fr) 2018-12-27
CL2019003332A1 (es) 2020-03-20
CN110831969B (zh) 2024-06-21
BR112019024410A2 (pt) 2020-07-14
AU2018288854A1 (en) 2019-11-21
JP2023071835A (ja) 2023-05-23
CA3062194A1 (fr) 2018-12-27
CN110831969A (zh) 2020-02-21
ZA201907259B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MA44154A (fr) Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
MA49460A (fr) Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
MA47314A (fr) Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur du glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
MA49459A (fr) Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
MA53661A (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
MA52003A (fr) Procédés de traitement de maladies associées au hpv
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
MA49256A (fr) Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
MA53234A (fr) Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
MA52953A (fr) Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques
MA53711A (fr) Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof